|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
WO2016168773A2
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
US11701387B2
(en)
|
2018-01-04 |
2023-07-18 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for BDCA2 antigen
|
|
WO2019152957A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
|
EP3775902B1
(en)
*
|
2018-04-04 |
2023-02-22 |
F. Hoffmann-La Roche AG |
Diagnostic assays to detect tumor antigens in cancer patients
|
|
US20210145830A1
(en)
*
|
2018-04-05 |
2021-05-20 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
CN112533602A
(zh)
|
2018-04-05 |
2021-03-19 |
大日本住友制药肿瘤公司 |
Axl激酶抑制剂及其用途
|
|
WO2019222642A1
(en)
*
|
2018-05-18 |
2019-11-21 |
Senti Biosciences, Inc. |
Engineered immune cells and methods of use
|
|
WO2020037178A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Memorial Sloan-Kettering Cancer Center |
Leucine zipper-based compositions and methods of use
|
|
EP4588483A3
(en)
*
|
2018-10-03 |
2025-09-24 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
|
|
WO2020092736A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CN111454909B
(zh)
*
|
2019-01-22 |
2024-12-10 |
北京大学深圳研究生院 |
天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
|
|
US20220133791A1
(en)
|
2019-01-23 |
2022-05-05 |
Miltenyi Biotec B.V. & Co. KG |
A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
EP3946382A1
(en)
|
2019-04-04 |
2022-02-09 |
UMC Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
CN110151999A
(zh)
*
|
2019-05-22 |
2019-08-23 |
中国人民解放军第四军医大学 |
用于抑制恶性黑色素瘤进展的靶向药物
|
|
CA3142108A1
(en)
|
2019-05-28 |
2020-12-03 |
Miltenyi Biotec B.V. & Co. KG |
Method for generation of genetically modified t cells
|
|
EP3997129B1
(en)
|
2019-07-11 |
2025-11-26 |
Valkyr, Inc. |
System and methods relating to chimeric autoantibody receptors
|
|
US20220315894A1
(en)
|
2019-09-11 |
2022-10-06 |
Miltenyi Biotec B.V. & Co. KG |
Method for Transduction of T Cells in the Presence of Malignant Cells
|
|
JP2023500799A
(ja)
*
|
2019-10-18 |
2023-01-11 |
トラスティーズ オブ ボストン ユニバーシティ |
Ｃａｌ－ｔコンストラクトおよびその使用
|
|
EP4073103A1
(en)
|
2019-12-11 |
2022-10-19 |
A2 Biotherapeutics, Inc. |
Lilrb1-based chimeric antigen receptor
|
|
TW202128131A
(zh)
*
|
2020-01-17 |
2021-08-01 |
大陸商信達生物制藥(蘇州)有限公司 |
重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
|
|
CN111234033B
(zh)
*
|
2020-01-21 |
2021-05-11 |
南京北恒生物科技有限公司 |
多链嵌合抗原受体及其用途
|
|
EP4100027A1
(en)
|
2020-02-04 |
2022-12-14 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
CN115397845A
(zh)
*
|
2020-02-20 |
2022-11-25 |
森迪生物科学公司 |
抑制性嵌合受体架构
|
|
CN115298209A
(zh)
*
|
2020-02-20 |
2022-11-04 |
森迪生物科学公司 |
抑制性嵌合受体构造体
|
|
JP2023518049A
(ja)
|
2020-03-16 |
2023-04-27 |
ユニバーシティ オブ サザン カリフォルニア |
新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
|
|
US20210322471A1
(en)
*
|
2020-03-27 |
2021-10-21 |
Dcprime B.V. |
In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
US20240252641A1
(en)
*
|
2020-05-05 |
2024-08-01 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
|
|
JP2023525910A
(ja)
|
2020-05-20 |
2023-06-19 |
ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー |
Ｃｄ９０およびｃｄ３２６を発現しているがんを処置するための組成物および方法
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
IL300484A
(en)
|
2020-08-19 |
2023-04-01 |
Astellas Pharma Inc |
A human non-naturally occurring modified IgG FC region that specifically binds to a non-naturally occurring modified FC receptor
|
|
AU2021328478A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
KR102859550B1
(ko)
|
2020-08-20 |
2025-09-16 |
에이투 바이오쎄라퓨틱스, 인크. |
Ceacam 양성 암을 치료하기 위한 조성물 및 방법
|
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
WO2022049217A1
(en)
|
2020-09-04 |
2022-03-10 |
Miltenyi Biotec B.V. & Co. KG |
System for inducible expression of an adapter in immune cells
|
|
WO2022081841A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Fred Hutchinson Cancer Research Center |
Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r1
|
|
US20230405047A1
(en)
|
2020-11-09 |
2023-12-21 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
AU2022211682A1
(en)
|
2021-01-22 |
2023-08-03 |
Mendus B.V. |
Methods of tumor vaccination
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
US11819578B2
(en)
|
2021-10-07 |
2023-11-21 |
Trustees Of Boston University |
Nanofiber scaffolds
|
|
WO2023062113A1
(en)
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
WO2023187031A1
(en)
|
2022-04-01 |
2023-10-05 |
Miltenyi Biotec B.V. & Co. KG |
A system for drug-inducible expression of a polynucleotide
|
|
WO2023217796A1
(en)
|
2022-05-10 |
2023-11-16 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
US20250339464A1
(en)
|
2022-05-16 |
2025-11-06 |
Miltenyi Biotec B.V. & Co. KG |
Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
|
|
EP4342488A1
(en)
|
2022-09-26 |
2024-03-27 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
EP4602171A1
(en)
|
2022-10-15 |
2025-08-20 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
US12115217B2
(en)
|
2022-11-18 |
2024-10-15 |
Trustees Of Boston University |
Self-replicating RNA and uses thereof
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
WO2025008108A1
(en)
|
2023-07-06 |
2025-01-09 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
|
|
EP4545963A1
(en)
|
2023-10-26 |
2025-04-30 |
Miltenyi Biotec B.V. & Co. KG |
Method for selecting antigen recognizing moieties having specificity for a target structure
|
|
WO2025224123A1
(en)
|
2024-04-25 |
2025-10-30 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptors specific for fibroblast activation protein
|
|
WO2025252326A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
|
|
WO2025252325A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
|